Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 16Prostate Cancer Metastatic 2Neoplasms 2Carcinoma, Transitional Cell 2Urinary Bladder Neoplasms 1Thrombocytosis 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphadenopathy 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hormone-Resistant Prostate Cancer 1Hodgkin Disease 1Hematologic Neoplasms 1Diarrhea 1Castrate-resistant Metastatic Prostate Cancer 1Breast Neoplasms 1Blast Crisis 1

Interventions

Octreotide 2cabazitaxel 1XRP6258 1Radiation 1Prednisone 1Fecal Microbiota Transplantation 1Diet Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diarrhea × XRP6258 × Genitourinary × Clear all
NCT01469338 2014-11-24

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

University of Southern California

Phase 2 Terminated
9 enrolled
Genitourinary

Diarrhea, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡